Forte Biosciences Inc (FBRX)
4.75
+0.38
(+8.70%)
USD |
NASDAQ |
Nov 05, 16:00
4.75
0.00 (0.00%)
After-Hours: 18:59
Forte Biosciences Enterprise Value: -18.12M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -18.12M |
| November 01, 2024 | -18.39M |
| October 31, 2024 | -18.00M |
| October 30, 2024 | -17.72M |
| October 29, 2024 | -17.81M |
| October 28, 2024 | -17.75M |
| October 25, 2024 | -17.67M |
| October 24, 2024 | -17.74M |
| October 23, 2024 | -17.45M |
| October 22, 2024 | -17.56M |
| October 21, 2024 | -17.72M |
| October 18, 2024 | -17.59M |
| October 17, 2024 | -17.93M |
| October 16, 2024 | -17.68M |
| October 15, 2024 | -17.76M |
| October 14, 2024 | -17.56M |
| October 11, 2024 | -17.85M |
| October 10, 2024 | -17.47M |
| October 09, 2024 | -17.20M |
| October 08, 2024 | -17.20M |
| October 07, 2024 | -17.18M |
| October 04, 2024 | -17.17M |
| October 03, 2024 | -17.20M |
| October 02, 2024 | -17.04M |
| October 01, 2024 | -16.96M |
| Date | Value |
|---|---|
| September 30, 2024 | -16.34M |
| September 27, 2024 | -16.12M |
| September 26, 2024 | -16.00M |
| September 25, 2024 | -14.86M |
| September 24, 2024 | -14.28M |
| September 23, 2024 | -14.23M |
| September 20, 2024 | -14.16M |
| September 19, 2024 | -14.27M |
| September 18, 2024 | -14.67M |
| September 17, 2024 | -14.15M |
| September 16, 2024 | -13.90M |
| September 13, 2024 | -13.87M |
| September 12, 2024 | -14.26M |
| September 11, 2024 | -14.13M |
| September 10, 2024 | -14.13M |
| September 09, 2024 | -13.43M |
| September 06, 2024 | -13.39M |
| September 05, 2024 | -13.37M |
| September 04, 2024 | -13.84M |
| September 03, 2024 | -13.40M |
| August 30, 2024 | -12.96M |
| August 29, 2024 | -13.11M |
| August 28, 2024 | -13.21M |
| August 27, 2024 | -11.90M |
| August 26, 2024 | -12.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.37M
Minimum
Nov 15 2023
540.23M
Maximum
Sep 28 2020
91.86M
Average
-11.50M
Median
Aug 12 2022
Enterprise Value Benchmarks
| Theriva Biologics Inc | -12.61M |
| CEL-SCI Corp | 50.50M |
| AIM ImmunoTech Inc | 8.843M |
| IGC Pharma Inc | 26.81M |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.51M |
| Total Expenses (Quarterly) | 12.82M |
| EPS Diluted (Quarterly) | -6.75 |
| Earnings Yield | -384.2% |